Introduction: This study aimed to investigate the causes, clinical management and outcomes
INTRODUCTION
Pericardial effusions are caused by a wide range of conditions and the distribution of these causes can vary globally. When complicated by tamponade, pericardiocentesis is potentially a life-saving intervention. There is limited data on patients with clinically significant pericardial effusions in Asia. The objectives of this study were to: (a) investigate the causes, clinical management and outcomes of clinically significant pericardial effusions; and (b) evaluate the practice of pericardiocentesis within an academic medical centre in Singapore, which is a multiethnic country in Southeast Asia.
METHODS
Consecutive patients undergoing pericardiocentesis at National University Heart Centre, Singapore (NUHCS) between August 2011 and February 2017 were identified from a comprehensive cardiac procedural database. Patient demographics, echocardiographic findings, investigations, pericardiocentesis procedural details and clinical progress were tracked using a comprehensive electronic medical records system. National University Hospital (NUH) is a 1,250-bedded academic medical centre in Singapore and provides tertiary services in oncology (National University Cancer Institute, Singapore) and cardiovascular medicine (NUHCS).
Echocardiographic findings of note that were recorded included ejection fraction, size of the pericardial effusion and the presence of tamponade physiology. The size of effusion was assessed semiquantitatively as mild (< 10 mm), moderate (10-20 mm) and large (> 20 mm) according to the measure of the largest echo-free space when viewed from the standard transthoracic echocardiographic windows.
(1) The presence of tamponade was assessed holistically using a range of indicators that included diastolic right heart collapse, abnormal ventricular septal motion, exaggerated inspiratory variability in mitral inflow velocity and inferior vena cava plethora.
Pericardiocentesis was guided either by using echocardiography alone or combined with fluoroscopy in the cardiac catheterisation laboratory upon the operator's discretion.
Echocardiographic guidance was used to identify the largest collection of the pericardial effusion that was closest to the skin surface without intervening lung or liver tissue. Images were acquired from both the apical and subcostal regions to identify the safest approach. The pericardiocentesis needle was then introduced according to the inclination of the echo probe to the expected depth where the effusion was seen. Occasionally, the needle tip was visualised by the echocardiography probe to confirm entry into the pericardial space, although this was not consistently demonstrated ( Fig. 1 ). Echocardiographic presence of the guidewire within the pericardial cavity was confirmed prior to insertion of the dilator. To further ensure correct placement of the sheath, agitated saline (bubble contrast) was injected through the smallest dilator to confirm presence of bubbles in the pericardial space before further dilatation was performed. For patients undergoing fluoroscopy-guided pericardiocentesis, fluoroscopy in the cardiac catherisation laboratory was used to localise the advancing needle in relation to the cardiac silhouette, combined with contrast injection to determine entry into the pericardial space and to verify the pericardial location of the guidewire by visualising it coiling around the pericardial sac (Fig. 2) . It was left to the operator's discretion whether echocardiography was Clinical progress, specifically recurrence of the effusion, need for repeated drainage and survival-to-discharge were recorded.
Patients were considered to have active cancer if the disease was diagnosed and treated within the past 12 months and the patient was in remission for less than 12 months. Patients were considered to have previously treated cancer if they were in remission for more than 12 months.
Continuous data was expressed as mean ± standard deviation. Continuous and categorical variables were assessed with unpaired t-test and Fisher's exact test, respectively.
GraphPad Prism version 7.0 (GraphPad Software Inc, San Diego, CA, USA) was used for all statistical analyses. The study received institutional ethics approval from the National Healthcare Group Domain Specific Review Board, Singapore (approval no. 2017/00535).
RESULTS
From August 2011 to February 2017, 149 patients with a mean age of 64.5 ± 15.7 years underwent pericardiocentesis (Table I) . Mean follow-up duration was 10.8 ± 13.2 months.
44.3% of patients were diagnosed with active cancer, and 6.0% of patients were considered to be in remission for over one year for previously treated cancer. More than half of cancers originated from the lung. Other common comorbidities included hypertension, hyperlipidaemia and coronary artery disease in 49.7%, 43.6% and 26.2% of patients, respectively. The most common presenting symptom was dyspnoea, reported by 51.0% of patients. *Data presented as mean ± standard deviation.
81.7% of patients had left ventricular ejection function within normal limits and 77.3%
of pericardial effusions were large in size (Table II) . Tamponade physiology was present in nearly 70% of patients. In the remaining patients, pericardiocentesis was performed for diagnostic purposes or symptom relief. Loculated effusions were seen in four out of nine patients who had developed effusions after cardiac surgery. Procedural success was achieved in all but one patient, and a mean 520 ± 408 mL of fluid was drained during the index procedure (Table III) . Subcostal approach was used in 47.7% of patients, and only 31.5% of patients were guided by both echocardiography and fluoroscopy. There were 3 (2.0%) serious complications, all of which required surgical interventions -two patients with right ventricular punctures (both using subcostal approach; one using echocardiographic guidance alone, and the other with both echocardiographic and fluoroscopic guidance) and one patient with left ventricular puncture (using an apical approach and echocardiographic guidance). All three patients survived to hospital discharge. In two patients, self-terminating atrial tachyarrhythmias occurred, which did not require any interventions. 76.9% of pericardial effusions were bloodstained, while the remainder was described as yellow or serous in appearance. No mycobacterial infection was found in our cohort. Out of 69 patients with malignant pericardial effusions, for only 31 (44.9%) patients were abnormal cytology reported. On comparing pericardial fluid from malignant effusions (which would be expected to be exudative) against those due to heart failure and uraemia (which would be expected to be transudative), there were no differences in cell counts and protein levels.
However, malignant pericardial effusions had lower glucose levels (malignant effusion: 4.0 ± 2.4 mmol/L; heart failure effusion: 7.0 ± 5.0 mmol/L; p < 0.01) and higher lactate dehydrogenase levels (malignant effusion: 3,181 ± 3,879 IU/L; heart failure effusion: 649 ± 501 IU/L; p < 0.01). There was significant overlap in both glucose and lactate dehydrogenase levels between the two groups.
The most common cause of pericardial effusion was due to malignancy, followed by iatrogenic complications of cardiovascular interventions (17.4%; Table IV ). In the latter, five patients were diagnosed following catheter ablation procedures for arrhythmias, four patients after percutaneous coronary arterial interventions, two patients post myocardial biopsy and the remaining 15 patients after cardiac surgery. Recurrences (24.6%) were observed most frequently in patients with malignant effusions, but repeat drainage was performed in only six out of 17 patients. One patient underwent surgery to create a pericardial window. Survival-todischarge was closely related to the aetiology, with the lowest survival rates seen among patients with acute ascending aortic syndrome (aortic dissections or rupture of ascending aortic aneurysms) and ventricular free wall rupture following acute myocardial infarctions. In contrast, all patients diagnosed with pericarditis, uraemia, heart failure and autoimmune causes survived to discharge. Survival rate at 12 months after pericardiocentesis for malignancy effusions was 45.0%. Causes of pericardial effusion vary depending on the geographical location of the survey. In less developed countries such as South Africa, infectious causes, such as tuberculosis, predominate. (2) Conversely, in advanced countries, complications of cardiac surgery and cancer are the most common causes. (3) (4) (5) Furthermore, the proportions of pericardial effusions caused by malignancy and postsurgical complications may be increasing over time, in part due to improved survival among cancer patients and increasing number of cardiac interventions in developed countries.
The prognosis of pericardial effusion is essentially related to its aetiology. (1, 7) Consistent with other series, patients with malignant pericardial effusions have poor prognosis with typical median survival of 3-7 months. (3) (4) (5) 7) This is consistent with a 45.0% survival rate at 12 months in our patients. However, patients presenting with haemopericardium due to acute ascending aortic syndrome, which namely consists of aortic dissections or rupture of aortic aneurysms, and free wall myocardial rupture had the worst short-term prognosis despite undergoing emergent surgery.
Our major complications rate of 2.0% was consistent with other large series, confirming the relative safety of pericardiocentesis. (4, 8) Given the low incidence of complications, it was not possible to discern whether the site of pericardial access or the additional use of fluoroscopy for guidance impacted upon complication rates. However, while complications are uncommon, three patients with incidental ventricular puncture required surgical repair in our series. This observation should be a cautionary note about performing non-emergent pericardiocentesis in hospitals without cardiothoracic surgical support.
While pericardial fluid is routinely sent for cell count, measurements of glucose, protein, lactate dehydrogenase levels, cytology and microbiological analyses, diagnostic yields are limited. All tests listed above, except cytology, generally lack specificity, with significant overlap between transudative and exudative effusions. (9) (10) (11) Conversely, cytological analyses have lower sensitivity -in this study, only 44.9% -but 100% specificity. The positive diagnostic yield of 44.9% from cytological analysis of malignant pericardial effusion in our study was consistent with the rate of 40%-50% in the literature. (5) Interpreting analyses of pericardial fluid are also limited by firstly, the fact that most causes of pericardial effusion would be expected to produce an exudative, typically bloodstained effusion (76.9% in this series) and secondly, that the biochemical composition of physiological pericardial fluid differs from plasma serum. (12) In a recent study, physiological pericardial fluid from 30 patients undergoing elective coronary artery bypass grafting, but without a history of pericardial disease, was collected. Surprisingly, pericardial lactate dehydrogenase levels were on average 2.4 times higher than serum levels while protein levels were only 60% of serum levels. (12) There was also predominant lymphocytosis, which was 5.3 times higher than paired serum levels.
This has led to several groups suggesting that analysis of pericardial biochemistry may be unhelpful or have almost no diagnostic value in the contemporary management of pericardial effusions. (10, 13) Our study was limited by its retrospective design, lack of a systematic protocol for pericardiocentesis and advanced investigations of the pericardial fluid. However, the findings reflect real-world practices and are informative for future improvements in clinical care. Our results may have been biased due to the presence of tertiary cancer and cardiovascular surgical services within our institution due to which higher proportions of patients with malignant and postsurgical effusions would be referred for pericardiocentesis.
In conclusion, cancer and iatrogenic complications are the most common causes of pericardial effusion in this large cohort of Singapore patients. Pericardiocentesis has a high success rate and relatively low complication rate. Prognosis and clinical course after pericardiocentesis is determined by the underlying cause of pericardial effusion. 
